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lmmunotherapy in infectious disease-novel 
treatment concepts 
Role of G-CSF in infection and inflammation 
T. Hartung. University .f Konstanz, Konstanz, Germany 
Objectives: G-CSF (Filgrastini) has been clinically used in approxi- 
mately 2 million patients within the last decade as a hematopoietic 
growth factor counteracting neutropenia and thereby reducing 
infectious episodes. The immunomodulatory properties of G-CSF 
treatment were studied in order to evaluate its putative use in non- 
neutropenic infection. 
Results: In more than 50 studies, G-CSF augmented immune 
defense also in non-neutropenic animals. Furthermore, the endo- 
genous formation of G-CSF appears to play an integral role in anti- 
infectious host defense. These preclinical data suggest the use of G- 
CSF also in humans suffering from non-neutropenic infections. The 
major concern that the neutrophilia induced by G-CSF treatment 
might endanger these patients by promoting the inflammatory res- 
ponses was disproved; it was shown, in contrast, that G-CSF displays 
overall anti-inflammatory characteristics. G-CSF treatment of 
rodents as well as humans favored anti-inflammatory cytokine release 
characterized by reduced bioactivity of TNF-alpha, IL-1, IL-12 and 
IFN-gamma. In addition, G-CSF-treated animals were protected in 
models of systemic inflammatory response syndromes and septic 
shock. 
Conclusions: Since in intensive care patients G-CSF treatment was 
found to be safe and associated with favorable clinical outcome, 
ongoing clinical studies are now evaluating the use of G-CSF 
treatment in non-neutropenic infections and chronic inflammatory 
disorders. 
lmmunotherapy of severe bacterial infections, 
sepsis and septic shock: G-CSF 
R. Root. University of Washington, Harborview Medical Center, Seattle, 
WA, C!SA 
Severe bacterial infections persist as a major cause ofillness and death 
throughout the world. Fatalities occur despite the appropriate use of 
antimicrobials. Recently, the difficulties in management has been 
further compounded by the emergence of resistant microorganisms. 
Knowledge of the pathogenesis of severe bacterial infections, sepsis 
and septic shock has promoted the development of immuno- 
therapeutic approaches as an adjunct to antibiotic treatment. Un- 
fortunately, despite a valid rationale and encouraging preliminary 
results, interventions designed to reduce the activity of pro- 
inflammatory mediators in sepsis, such as TNF and IL-1, have been 
disappointing. One of the difficulties in evaluating these studies has 
been the heterogeneous nature of the populations studied. Many 
patients may meet criteria for sepsis, but do not have microbiological 
evidence of infection; furthermore, they may be in different stages of 
their illness. Investigations employing patients with bacterial 
pneumonia can surmount these limitations, by using strict criteria for 
diagnosis and determination of etiologic agents, and early entry into 
treatment protocols. G-CSF is a compound that has targeted pro- 
inflammatory activities related to enhancement of neutrophil 
production and antimicrobial functions, while reducing some of the 
deleterious consequences of uncontrolled inflammation. Large 
studies using patients with community-acquired pneumonia, includ- 
ing those with multilobar pneumonia or sepsis, have indicated 
improved therapeutic responses and a reduced incidence of septic 
complications. The results of a recently completed, multicenter, 
double-blind, placebo-controlled trial of G-CSF as an adjunct to 
antibiotics in the treatment of patients with severe bacterial 
pneumonia and sepsis will be presented and discussed. 
(s1411 lmmunotherapy of disseminated candidiasis; 
results of a double-blind, randomized, placebo- 
controlled study 
B.J. Kullberg. University Hospital Nijmegen, Dept of Medicine, 
Nijmegen, The Netherlands 
Granulocyte colony-stimulating factor enhances the antifungal 
activity of neutrophils. We assessed the role of recombinant human 
G-CSF (filgrastim) in conjunction with fluconazole for the treatment 
of patients with invasive candidiasis and candidemia. In a placebo- 
controlled study, non-neutropenic patients with documented invasive 
candida infection were randomized to treatment with either 
filgrastim and fluconazole or placebo and fluconazole. O f  the 51 
patients randomized into the study, resolution of infection on day 28 
was 14 (67%) for filgrastim-treated patients and 15 (50%) for placebo- 
treated patients. Patients treated with filgrastim were suggested to 
have a decreased time to resolution of candidiasis compared with 
patients receiving placebo (median 14 versus 21 days, hazard ratio 
(HR) 1.88; 95% CI, 0.90, 3.92). Patients who achieved a rise in 
leukocyte numbers of at least l5XlOy/L during therapy had a 
significantly greater chance of resolution of infection (HR, 2.77; 95% 
CI, 1.30, 5.92) and a significantly reduced mortality (HR 0.09, 95% 
C1, 0.014.66). When adjusted for covariates, evaluable patients in 
the filgrastim arm had a significantly greater chance of success or 
improvement on day 56 than did placebo-treated patients (p0.011). 
In non-neutropenic patients, there is a strong correlation between 
white blood cell counts and the outcome of candidiasis. Filgrastim 
may be beneficial in treating patients with candidemia or invasive 
candidiasis. 
)s1421 Randomized trial of G-CSF in diabetic foot 
infection 
M. Ednionds, M. Clapperton, N. Rolando, A. Foster, 
J. Philpott-Howard, A. Gough. Diabetic Department, King’s Collep 
Hospital, London, UK 
Objectives: Tp assess G-CSF as adjuvant therapy for the treatment 
of severe foot infections in diabetic patients. 
Methods: Forty diabetic patients with foot infections were 
enrolled in a double-blind placebo-controlled study. O n  admission, 
patients were randomly assigned G-CSF (filgrastim) therapy (n=20) 
or placebo (n=20) for 7 days. Both groups received siindar antibiotic 
and insulin treatment. Neutrophils from the peripheral blood were 
stimulated with opsonized zymosan, and superoxide production was 
measured by a spectrophotometric assay G-CSF therapy was 
associated with earlier eradication of pathogens from infected ulcer 
(median 4 (range 2-10) versus 8 (2-79) days in the placebo group; 
p=0.02), quicker resolution of cellulitis (7 (5-20) versus 12 (5-93) 
days; p=0.03), shorter hospital stay (10 (7-31) versus 17.5 (9-100) 
days; p=0.02), shorter duration of intravenous antibiotic treatment 
(8.5 (5-30) versus 14.5 (8-63) days; ~ ~ 0 . 0 2 ) .  No G-CSF-treated 
patient needed surgery compared with four in the placebo group. 
After 7 days of treatment, neutrophil superoxide production was 
higher in the G-CSF group than in the placebo group (16.1 
(4.2-24.2) versus 7.3 (2.1-11.5) at 30 min; p<0.0001). G-CSF 
therapy was generally well tolerated. 
